Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 2:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 331 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Mood Disorder, Psychotic Clear all
Completed Phase 4 Interventional Results available

Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia

NCT05859698
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder, Tardive Dyskinesia
Interventions
Valbenazine
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
18
States / cities
Bryant, Arkansas • Anaheim, California • Orange, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Sep 26, 2026, 2:35 PM EDT
Completed Phase 3 Interventional

The Study of Olanzapine Plus Fluoxetine in Combination for Treatment of Treatment Resistant Depression

NCT00035321
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Olanzapine, Fluoxetine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
30
States / cities
Oceanside, California • San Marcos, California • Torrance, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2006 · Synced Sep 26, 2026, 2:35 PM EDT
Completed Not applicable Interventional

Contingency Management for Problematic Behavior Reduction in the Community

NCT06486584
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder, Anosognosia
Interventions
Contingency Management
Behavioral
Lead sponsor
Laureate Institute for Brain Research, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Sep 26, 2026, 2:35 PM EDT
Recruiting Phase 4 Interventional

Exercise and Olanzapine-samidorphan

NCT06740890
View directory record Official record
Conditions
Schizophenia Disorder, Schizoaffective Disorder, Bipolar Disorder I or II, Bipolar Disorder NOS
Interventions
Olanzapine-samidorphan + exercise
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 26, 2026, 2:35 PM EDT
Withdrawn Not applicable Interventional

Prevention of Weight Gain and Dyslipidemia by Green Tea in Patients Initiating Therapy With Olanzapine

NCT00934908
View directory record Official record
Conditions
Bipolar Disorder, Schizophrenia
Interventions
Green Tea, Placebo
Dietary Supplement · Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Sep 26, 2026, 2:35 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Reliability and Validity of the MINI International Neuropsychiatric Interview for Children and Adolescents (MINI-KID)

NCT00579267
View directory record Official record
Conditions
Major Depression, Mania, Anxiety Disorders, Psychotic Disorder, Alcohol Dependence, Drug Dependence, Eating Disorders, Suicidality, Dysthymia, ADHD, Tourettes Disorder, Conduct Disorder, Oppositional Defiant Disorder, Pervasive Developmental Disorder
Interventions
MINI-KID
Other
Lead sponsor
University of South Florida
Other
Eligibility
6 Years to 17 Years
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 15, 2009 · Synced Sep 26, 2026, 2:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Targeting Cerebellum to Treat Psychosis: a Transcranial Magnetic Stimulation (TMS) Study

NCT02642029
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder I
Interventions
Excitatory TMS, Inhibitory TMS, Sham TMS
Device
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 50 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
2
States / cities
Belmont, Massachusetts • Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 29, 2022 · Synced Sep 26, 2026, 2:35 PM EDT
Suspended Phase 1Phase 2 Interventional

D-serine AudRem: R33 Phase

NCT05046353
View directory record Official record
Conditions
Schizophrenia, Schizo Affective Disorder
Interventions
D-serine, Placebo
Drug · Other
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 26, 2026, 2:35 PM EDT
Completed Phase 1 Interventional

Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants

NCT02087579
View directory record Official record
Conditions
Psychotic Disorders, Schizophrenia, Bipolar Disorder, Depressive Disorder
Interventions
Aripiprazole, oral formulation, Olanzapine, oral formulation, Paliperidone, oral formulation, Paliperidone, LAI, Quetiapine, oral formulation, Risperidone, oral formulation, Risperidone, LAI
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
6
States / cities
Garden Grove, California • Kissimmee, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2015 · Synced Sep 26, 2026, 2:35 PM EDT
Completed Phase 3 Interventional Results available

Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia

NCT04268303
View directory record Official record
Conditions
Agitation, Schizophrenia, Schizo Affective Disorder, Schizoaffective Disorder, Schizophreniform Disorders
Interventions
Sublingual film containing dexmedetomidine (BXCL501), Placebo Film
Drug
Lead sponsor
BioXcel Therapeutics Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
15
States / cities
Little Rock, Arkansas • Cerritos, California • Culver City, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 26, 2026, 2:35 PM EDT
Completed No phase listed Observational

Adherence in Patients Admitted to a Psychiatric Unit for Acute Psychosis: an Analysis of Serum Levels of Antipsychotics.

NCT01786369
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
Interventions
Not listed
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2015 · Synced Sep 26, 2026, 2:35 PM EDT
Not listed Phase 4 Interventional

DIMES - DIgital MEdicine Study for Adults With Schizophrenia, Bipolar I Disorder, or Major Depression Currently Using Aripiprazole

NCT03881449
View directory record Official record
Conditions
Schizophrenia, Major Depressive Disorder, Bi-Polar Disorder, Schizo Affective Disorder
Interventions
ABILIFY MYCITE
Combination Product
Lead sponsor
Durham VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Durham, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 17, 2020 · Synced Sep 26, 2026, 2:35 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Ascertaining Diagnosis Classification With Elicited Speech

NCT05601063
View directory record Official record
Conditions
Schizophrenia Spectrum and Other Psychotic Disorders, Bipolar and Related Disorders, Depressive Disorder, Anxiety Disorders, Personality Disorders, Attention Deficit Hyperactivity Disorder
Interventions
Winterlight Speech Assessment
Behavioral
Lead sponsor
Northwell Health
Other
Eligibility
14 Years to 50 Years
Enrollment
255 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Oct 31, 2022 · Synced Sep 26, 2026, 2:35 PM EDT
Completed Not applicable Interventional

Contingency Management of Psychostimulant Abuse in the Severely Mentally Ill

NCT00809770
View directory record Official record
Conditions
Drug Abuse, Schizophrenia, Bipolar Disorder, Major Depressive Disorder
Interventions
Contingency Management, Non Contingent Control Condition
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 65 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 7, 2016 · Synced Sep 26, 2026, 2:35 PM EDT
Completed Phase 1 Interventional

A Study of SEP-380135 in Adults With Schizophrenia or Major Depressive Episode

NCT07549581
View directory record Official record
Conditions
Schizophrenia, Major Depressive Disorder (MDD), Bipolar Disorder
Interventions
SEP-380135, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Los Alamitos, California
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Sep 26, 2026, 2:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Individualizing Incentives for Alcohol in the Severely Mentally Ill

NCT03481049
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder, Major Depressive Disorder, Alcohol Dependence
Interventions
Usual CM, High-Magnitude CM, Shaping CM
Behavioral
Lead sponsor
Washington State University
Other
Eligibility
18 Years to 65 Years
Enrollment
392 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
2
States / cities
Seattle, Washington • Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Aug 10, 2025 · Synced Sep 26, 2026, 2:35 PM EDT
Completed Phase 2 Interventional Results available

Study in Stabilized Schizophrenic Patients to Evaluate the Pharmacokinetics of Risperidone and 9-Hydroxy (OH)-Risperidone When Risperidone is Administered From a Polyurethane Implant

NCT02658357
View directory record Official record
Conditions
Schizophrenia, Schizo-affective Disorder
Interventions
Risperidone Implant
Drug
Lead sponsor
Braeburn Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Hollywood, Florida
Source: ClinicalTrials.gov public record
Updated Feb 18, 2020 · Synced Sep 26, 2026, 2:35 PM EDT
Completed Not applicable Interventional

Behavioral Treatment of Drug Abuse in Severe and Persistent Mental Illness (SPMI) Patients

NCT00295139
View directory record Official record
Conditions
Schizophrenia, Mood Disorders, Substance Dependence
Interventions
Behavioral Treatment for Substance Abuse in SPMI (BTSAS), Supportive Treatment in Addiction Recovery (STAR), Critical Time Intervention (CTI)
Behavioral
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 55 Years
Enrollment
293 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
4
States / cities
Baltimore, Maryland • Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 17, 2022 · Synced Sep 26, 2026, 2:35 PM EDT
Completed Phase 3 Interventional Results available

Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Adults With Major Depressive Disorder and Anxiety Symptoms

NCT02013531
View directory record Official record
Conditions
Major Depressive Disorder, Anxiety
Interventions
Brexpiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
21
States / cities
Tuscon, Arizona • Garden Grove, California • Oceanside, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2016 · Synced Sep 26, 2026, 2:35 PM EDT
Completed Phase 1 Interventional

Bio-equivalence Study Between SAPHRIS and Asenapine

NCT01948024
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder
Interventions
SAPHRIS, Asenapine
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years to 80 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
7
States / cities
Little Rock, Arkansas • Costa Mesa, California • Garden Grove, California + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2021 · Synced Sep 26, 2026, 2:35 PM EDT
Completed Not applicable Interventional Results available

Probiotics to Prevent Relapse After Hospitalization for Mania

NCT01731171
View directory record Official record
Conditions
Bipolar Disorder, Schizoaffective Disorder
Interventions
Probiotic Supplement, Inert Compound
Dietary Supplement
Lead sponsor
Sheppard Pratt Health System
Other
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 6, 2019 · Synced Sep 26, 2026, 2:35 PM EDT
Completed Phase 4 Interventional Results available

Fixed Dose Intervention Trial of New England Enhancing Survival in SMI Patients

NCT02188121
View directory record Official record
Conditions
Serious Mental Illness, Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Cardiovascular Disease, Major Depressive Disorder, Psychosis NOS
Interventions
Simvastatin, Losartan
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 89 Years
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 29, 2023 · Synced Sep 26, 2026, 2:35 PM EDT
Completed Not applicable Interventional Results available

Restoration of Cognitive Function With TDCS and Training in Serious Mental Illness

NCT03208036
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder, Schizo Affective Disorder
Interventions
TDCS, Sham Stimulation, Cognitive Remediation, Bridging Group
Device · Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Sep 26, 2026, 2:35 PM EDT
Not listed Phase 4 Interventional

Evaluating Sublingual Dexmedetomidine For Moderate To Severe Agitation In Inpatients With Schizophrenia Or Bipolar Disorder

NCT06093451
View directory record Official record
Conditions
Schizophrenia Agitation, Schizo Affective Disorder, Bipolar Disorder, Dexmedetomidine
Interventions
Dexmedetomidine, Lorazepam 2 MG/ML
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 22, 2023 · Synced Sep 26, 2026, 2:35 PM EDT